Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERAS-456 in Adults Treated for Pulmonary Tuberculosis
NCT02375698Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AERAS-456 in Tuberculosis (TB), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Number of Participants With Adverse Events and Serious Adverse Events. Started Nov 2014; status: completed.
02
Drugs
AERAS-456
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02375698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375698.